Environmental Monitoring Home / About Protalix / Environmental Monitoring ENVIRONMENTAL MONITORING The Pollutant Release and Transfer Register (PRTR) is an environmental database or inventory of potentially hazardous chemical substances and/or pollutants released to air, water and soil and transferred off-site for treatment or disposal. Industrial or business facilities are required to quantify and report the amounts of substances released to each environmental medium (air, water and soil) or transferred off-site for waste management or wastewater treatment. The objective of PRTR is to provide the public access to this data. PRTR principles were established under UNECE Kiev protocol and in Israel the PRTR was anchored under the 2012 environmental protection law. Protalix PRTRs: 2012 2013 2014 2015 ABOUT About Protalix Management Board of Directors Scientific Advisory Board TECHNOLOGY ProCellEx® Platform From Concept to Market PIPELINE Pipeline Pegunigalsidase alfa (PRX-102) Alidornase alfa (PRX-110) OPRX-106 Expanded Access CONTACT Contact Us Collaborations © 2021 Plant-Based Proteins with Better Therapeutic Profiles | Privacy Policy | Terms of use Site by CadenSee - Let's Talk Medical

Skip to main navigation Overview Home /Overview OVERVIEW Protalix is a biopharmaceutical company focused on the development and commercialization of proprietary recombinant therapeutic proteins expressed through its proprietary ProCellEx® plant cell-based protein expression system. Using ProCellEx, Protalix is developing a pipeline of novel proteins that target large, established pharmaceutical markets and that rely upon known biological mechanisms of action. Our initial commercial focus has been on complex therapeutic proteins, including proteins for the treatment of genetic disorders, such as Gaucher disease and Fabry disease. We believe our ProCellEx protein expression system will enable us to develop proprietary recombinant proteins that are therapeutically equivalent or superior to existing recombinant proteins currently marketed for the same indications. Because we are primarily targeting biologically equivalent versions of highly active, well-tolerated and commercially successful therapeutic proteins, we believe our development process is associated with relatively less risk compared to other biopharmaceutical development processes for completely novel therapeutic proteins. UPCOMING EVENTS More events are coming soon. STOCK QUOTE NYSE MK TASE Shareholder Tools Print Page RSS Feeds E-mail Alerts ABOUT About Protalix Management Board of Directors Scientific Advisory Board TECHNOLOGY ProCellEx® Platform From Concept to Market PIPELINE Pipeline Pegunigalsidase alfa (PRX-102) AIR DNase (PRX-110 ) OPRX-106 CONTACT Contact Us Collaborations © 2021 Protalix Ltd. All rights reserved. | Privacy Policy | Terms of use